Hasten Biopharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 2020-09-16
- Employees
- -
- Market Cap
- -
- Website
- https://www.hastenpharma.com
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Phase 3
Recruiting
- Conditions
- HypercholesterolemiaHyperlipidemia; MixedASCVDDyslipidemiasMetabolic DiseaseHeterozygous Familial HypercholesterolemiaPrimary Hypercholesterolemia
- Interventions
- Drug: matching placebo
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT06568471
- Locations
- 🇨🇳
Beijing Anzhen Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital, Capital Medical Univeristy, Beijing, Beijing, China
🇨🇳Beijing Tsinghua Changgeng Hospital, Beijing, Beijing, China
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06504043
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
Recruiting
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 1215
- Registration Number
- NCT05947448
- Locations
- 🇨🇳
Junbo Ge, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath